Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 4 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Results 1 - 20 of 329 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

1
Member Avatar shotgun06 (< 20) Submitted: 7/23/2014 4:20:17 PM : Outperform Start Price: $91.56 GILD Score: +0.41

Look at the products that they have and have in trials. The need for these products are very large!

Recs

1
Member Avatar AtomicBlicky (21.35) Submitted: 7/22/2014 7:56:24 PM : Outperform Start Price: $80.92 GILD Score: +10.12

Have top drugs for top ailments. Cash cow! Yeeeeeha!!

Recs

1
Member Avatar shroff33 (< 20) Submitted: 7/20/2014 5:01:33 PM : Outperform Start Price: $89.80 GILD Score: +1.49

GILD will prevail over competition from ABBV and MRK.

Recs

0
Member Avatar DPGuinee (27.16) Submitted: 7/10/2014 6:13:27 PM : Underperform Start Price: $89.32 GILD Score: -1.68

Ridiculous earnings 1Q14 cannot be matched, esp w competition looming. Price may continue to rise, but won't keep pace.

Recs

0
Member Avatar zzgorch (40.44) Submitted: 6/30/2014 2:13:05 PM : Outperform Start Price: $83.38 GILD Score: +8.80

Strong EPS, well below market Forward P/E (10.72) and a PEG well under one (0.46). Gilead is finding actual cures for nasty diseases (Hepatitis C) and has HUGE upside potential. Wish I had the funds to buy on the drop early this spring but there is plenty of room to run. It should get up to 100 by year end.

Recs

0
Member Avatar bdescent (69.72) Submitted: 6/27/2014 8:37:32 PM : Outperform Start Price: $82.79 GILD Score: +9.35

Nice pipeline.

Recs

0
Member Avatar rbitrage (63.91) Submitted: 6/22/2014 9:20:14 PM : Outperform Start Price: $81.27 GILD Score: +11.60

Sovaldi. In spite of the fact charging so much for a drug should be illegal, it isn't. Gilead recognizes this and making a mint. Sovaldi actually cures Hep-C (most of the time) and the bad press has been fantastic advertising. Our country might go broke paying for drugs like this, but in the meantime, companies like Gilead will be laughing- all the way to the bank.

Recs

0
Member Avatar Investinguppy (< 20) Submitted: 6/17/2014 11:01:54 PM : Outperform Start Price: $79.85 GILD Score: +13.02

Solvaldi will surprise to the upside and is first to market. Promising pipeline.

Recs

0
Member Avatar iksnamyzs (78.52) Submitted: 6/16/2014 5:45:51 PM : Outperform Start Price: $80.73 GILD Score: +11.34

high but higher still

Recs

0
Member Avatar Jmaltsman (63.44) Submitted: 6/10/2014 5:05:46 PM : Outperform Start Price: $79.36 GILD Score: +13.76

Great company with large international presence. The stock is undervalued relative to forecasted revenue growth.

Recs

0
Member Avatar coachtom4 (63.26) Submitted: 6/9/2014 11:09:07 AM : Outperform Start Price: $78.83 GILD Score: +14.96

Assuming they come even close to analysts projections of earnings, they will have a single digit P/E in 19 months with significant growth.

Recs

0
Member Avatar cajun1958 (33.66) Submitted: 5/25/2014 12:52:16 PM : Underperform Start Price: $82.08 GILD Score: -7.89

They have the HIV & HCV treatments down but beed something new. HCV & HIV are common diseases and there is a huge market but as patents begin to expire, GILD becomes another ENDO or GSK.

Recs

0
Member Avatar 10x2 (33.66) Submitted: 5/15/2014 12:28:27 PM : Outperform Start Price: $79.89 GILD Score: +8.60

Mega growth story.

Recs

0
Member Avatar investomania (88.17) Submitted: 5/14/2014 9:56:14 PM : Outperform Start Price: $81.02 GILD Score: +8.05

Sometimes investing is simple. Revenues and profits are ramping up dramatically due to the best cure for Hepatitis C and the best preventative medication against HIV infection. Thanks to the recent pullback in all things biotech, the price is right. There's limited downside and a lot of room to run.

Recs

0
Member Avatar km00nster (< 20) Submitted: 5/8/2014 7:57:00 PM : Outperform Start Price: $71.71 GILD Score: +20.16

Very Very Very under-valued stock that should outperform in the long-term. If I was to put all my money into one stock, this would be it.

Recs

0
Member Avatar Pluto7 (33.99) Submitted: 5/8/2014 4:52:14 PM : Outperform Start Price: $78.81 GILD Score: +10.66

they have really good products and revenue

Recs

0
Member Avatar sungura2005 (28.21) Submitted: 5/2/2014 2:37:09 PM : Outperform Start Price: $77.43 GILD Score: +12.97

Sovalsi

Recs

0
Member Avatar 1russianguy (59.91) Submitted: 5/2/2014 10:39:04 AM : Outperform Start Price: $78.07 GILD Score: +5.71

05/02/14 Cheap growth screen.

Recs

0
Member Avatar 2gud2btrue (77.29) Submitted: 4/23/2014 9:39:20 AM : Outperform Start Price: $75.24 GILD Score: +16.19

Certainly something to explore more but looks a winner in the long run. Worth buying at a dip here.

Recs

0
Member Avatar leaderoftheback (86.41) Submitted: 4/19/2014 6:56:55 AM : Outperform Start Price: $70.38 GILD Score: +23.86

It's all priced in, but I think this one will still outperform the market, short term. I'd be buying on a dip around $58.

Featured Broker Partners


Advertisement